Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced dna adducts in vitro

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1487-1494

  Li, Lan ^a   Liu, Xiao Ming ^a   Glassman, Armand B ^a   Keating, Michael J ^a   Stros, Michal ^b   Plunkett, William ^a   Yang, Li Ying ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUDARABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DNA ADDUCT; DNA CROSS LINKING; DRUG DNA BINDING; DRUG EFFICACY; DRUG POTENTIATION; EXCISION REPAIR; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL;

ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CISPLATIN; CYTIDINE MONOPHOSPHATE; DNA ADDUCTS; DNA REPAIR; HIGH MOBILITY GROUP PROTEINS; HUMANS; PLASMIDS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0030983004     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jones, J., Zhen, W., Reed, E., Parker, R. J., Sancar, A., and Bohr, V. A. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem., 266: 7101-7107, 1991.
2. Roberts, J. J. Molecular mechanisms of action of anti-tumor platium compounds. In: C. Chagas and B. Pullman (eds.), Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity, pp. 463-489. Vatican City, Italy: Pontificia Academia Scientiarvm, 1987.
3. Weeda, G., and Hoeijmakers, H. J. Genetic analysis of nucleotide excision repair in mammalian cells. Semin. Cancer Biol., 4: 105-117, 1993.
4. Johnson, S. W., Perez, R. P., Godwin, A- K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
5. Calsou, P., Barret J-M., Cros, S., and Salles, B. DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur. J. Biochem., 211: 403-409, 1993.
6. Yang, L-Y., Li, L., Keating, M. J., and Plunkett, W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair Mol. Pharmacol., 47: 1072-1079, 1995.
7. Van Houten, B. Nucleotide excision repair in Escherichia coli. Microbiol. Rev., 51: 18-51, 1990.
8. Hansson, J., and Wood, R. D. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II). Nucleic Acids Res., 20: 8073-8091, 1989.
9. Visse, R., Van Gool, A. J., Moolenaar, G. I., deRuijter, M., and van de Putte, P. The actual incision determines the efficiency of repair of cisplatin-damaged DNA by the Escherichia coli Uvr ABC endonuclease. Biochemistry, 33: 1804-1811, 1994.
10. Friedberg, E. C. Relationships between DNA repair and transcription. Annu. Rev. Biochem., 65: 15-42, 1996.
11. Sancar, A. DNA excision repair. Annu. Rev. Biochem., 65: 43-81, 1996.
12. Wood, R. D. DNA repair in eukaryotes. Annu. Rev. Biochem., 65: 135-167, 1996.
13. Robins, P., Jones, C. J., Biggerstaff, M., Lindahl, T., and Wood, R. Complementation of DNA repair in xeroderma pigmentosum group A cell extracts by a protein with affinity for damaged DNA. EMBO J., 10: 3913-3921, 1991.
14. Guzder, S. N., Sung, P., Prakash, L., and Prakash, S. Yeast DNA-repair gene RAD14 encodes a zinc metalloprotein with affinity for ultraviolet-damaged DNA. Proc. Natl. Acad. Sci. USA, 90: 5433-5437, 1993.
15. Li, L., Lu, X., Peterson, C. A., and Legerski, R. J. An interaction between the DNA repair factor XPA and replication protein A appears essential for nucleotide excision repair Mol. Cell. Biol., 15: 5396-5402, 1995.
16. Mu, D., Hsu, D. S., and Sancar, A. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem., 271: 8285-8294, 1996.
17. Li, L., Elledge, S. J., Peterson, C. A., Bales, E. S., and Legerski, R. J. Specific association between the human DNA repair proteins XPA and ERCC1 Proc. Natl. Acad. Sci. USA, 91: 5012-5016, 1994.
18. Park, C. H., and Sancar, A. Formation of a ternary complex by human XPA, ERCC1 and ERCC4 (XPF) excision repair proteins. Proc. Natl. Acad. Sci. USA, 91: 5017-5012, 1994.
19. 2 encodes a single-stranded DNA endonuclease. Nature (Lond.), 366: 365-368, 1993.
20. O-Donovan, A., Scherly, D., Clarkson, S. G., and Wood, R. D. Isolation of active recombinant XPG protein, a human DNA repair endonuclease. J. Biol. Chem., 269: 15965-15968, 1991.
21. Habraken, Y., Sung, P., Prakash, L., and Prakash, S. Human xeroderma pigmentosum group G gene encodes a DNA endonuclease. Nucleic Acids Res., 22: 3312-3316, 1994.
22. Park, C-H., Bessho, T., Matsunaga, T., and Sancar, A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem., 29: 22657-22660, 1995.
23. Shivji, M. K. K., Kenny, M. K., and Wood, R. D. Proliferating cell nuclear antigen is required for DNA excision repair. Cell, 69: 367-374, 1992.
24. Nichols, A. F., and Sancar, A. Purification of PCNA as a nucleotide excision repair protein. Nucleic Acids Res., 20: 2441-2446, 1992.
25. Shivji, M. K. K., Podust, V. N., Hübscher, U., and Wood, R. D. Nucleotide excision repair DNA synthesis by DNA polymerase ε in the presence of PCNA, RFC, and RPA, Biochemistry, 34: 5011-5017, 1995.
26. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, M., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J., and McCredie, K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 747: 19-25, 1989.
27. Keating, M. J., McLaughlin, P., Plunkett, W., Robertson, L. E., O'Brien, S., Gandhi, V., Gregoire, V., Yang, L-Y., and Cabanillas, F. Fludarabine: present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann. Oncol., 5: S79-S83, 1994.
28. Huang, P., Chubb, S., and Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. J. Biol. Chem., 265: 16617-16625, 1990.
29. Catapano, C., Perrino, F. W., and Fernandes, D. J. Primer RNA chain termination induced by 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate: a mechanism of DNA synthesis inhibition. J. Biol. Chem., 268: 7179-7185, 1993.
30. Yang, S. W., Huang, P., Plunkett, W., Becker, F., and Chan, Y. H. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J. Biol. Chem., 267: 2345-2349, 1992.
31. Plunkett, W., Gandhi, V., Huang, P., Robertson, L. E., Yang, L-Y., Gregoire, V., Estey, E., and Keating, M. J. Fludarabine: pharmacokinetics, mechanism of action and rationales for combination therapies. Semin. Oncol., 20 (Suppl. 7): 2-12, 1993.
32. Huang, J. C., Zamble, D. B., Reardon, J. T., and Lippard, S. J., and Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad Sci. USA, 91: 10394-10398, 1994.
33. Pil, P. M., and Lippard, S. J. Specific binding of chromosomal protein HMG1 to DNA damaged by anticancer drug cisplatin. Science (Washington DC), 256: 234-237, 1992.
34. Chu, G. Cellular responses to cisplatin: the roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 269: 787-790, 1994.
35. Turchi, J. J., Li, M., and Henkels, K. M. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry, 35: 2992-3000, 1996.
36. Novotny, L., and Plunkett, W. In: L. B. Townsend and R. S. Tipson (eds.), Nucleic Acid Chemistry, part 4, pp. 337-340. New York: John Wiley and Sons, 1990.
37. Stros, M., and Vorlickova, M. Non-histone chromosomal protein HMG1 reduces the histone H5-induced changes in c.d. spectra of DNA: the acidic C-terminus of HMG1 is necessary for binding to H5. Int. J. Biol. Macromol., 12: 282-288, 1990.
38. Stros, M., Stokrova, J., and Thomas, J. O. DNA looping by the HMG-box domains of HMG1 and modulation of DNA binding by the acidic C-terminal domain. Nucleic Acids Res., 22: 1044-1051, 1994.
39. Sing, J., and Dixon, G. H. High mobility group proteins 1 and 2 function as general class II transcription factors. Biochemistry, 29: 6295-6302, 1990.
40. Yang, L-Y., Liu, Y. Z., Kantarjian, H. H., and Keating, M. J. DNA cross-linking and repair in cisplatin-resistant human cells following exposure to a new cisplatin analogue, CI-973. Int. J. Oncol., 5: 597-602, 1994.
41. Yang, L-Y., Trujillo, J. M., Siciliano, M. J., Kido, Y., Siddik, Z. H., and Su, Y. Z. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma. Int. J. Cancer, 53: 478-485, 1993.
42. Robine, P., Jones, C. J., Biggerstaff, M., Lindahl, T., and Wood, R. D. Complementation of DNA repair in xeroderma pigmentosum group A cell extracts by a protein with affinity for damaged DNA. EMBO J., 10: 3913-3921, 1991.
43. Manley, J. L., Fire, A., Samuels, M., and Sharp, P. A. In vitro transcription: whole cell extract. Methods Enzymol., 101: 568-582, 1983.
44. Calsou, P., and Salles, B. Measurement of damage-specific DNA incision by nucleotide excision repair in vitro. Biochem. Biophys. Res. Commun., 202: 788-795, 1994.
45. Wood, R. D., Robins, P., and Lindahl, T. Complementation of xeroderma pigmentosum DNA repair defect in cell-free extract. Cell. 53: 97-106, 1988.
46. Sancar, A. Excision repair in mammalian cells. J. Biol. Chem., 270: 15915-15918, 1995.
47. Svoboda, D. L., Taylor, J. S., Hearst, J. E., and Sancar, A. DNA repair by eukaryotic nucleotide excision nuclease-removal of thymidine dimer and psoralen monoadduct by HeLa cell-free extract and of thymine dimer by Xenopus lavis oocytes. J. Biol. Chem., 268: 1931-1936, 1993.
48. Kasparkova, J., and Brabec, V. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum (II) and its trans isomer by DNA-binding proteins. Biochemistry, 34: 12379-12387, 1995.
49. Moggs, J. G., Yarema, K. J., Essigmann, J. M., and Wood, R. D. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J. Biol. Chem., 271: 7177-7186, 1996.
50. Gandhi, V., Kemena, A., Keating, M. J., and Plunkett, W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia Lymphoma, 10: 49-56, 1993.
51. Danhauser, L., Plunkett, W., Keating, M. J., and Cabanillas, S. 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol., 18: 145-152, 1986.
52. Avramis, V. I., Champagne, J., Sato, J., Krailo, M., Ettinger, L. J., Poplack, D. G., Finklestein, J., Reaman, G., Hammond, D., and Holcenberg, J. S. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res., 50: 7226-7231, 1990.
53. Gandhi, V., and Plunkett, W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem. Pharmacol., 38: 3551-3558, 1989.